H.C. Wainwright analyst Matthew Keller downgraded Iterum Therapeutics (NASDAQ: ITRM) from Buy to Neutral.The analyst comments "We are downgrading to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE